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ABSTRACT
Objective: Mechanistic study of newly reported anti-Parkinson agents by molecular docking to predict possible target.
Methods: Structures of newer drugs known anti-Parkinson agents were drawn using ChemBioDraw 2D software. Thereafter, they were converted to 
3D structures using ChemBioDraw 3D software in which they were subjected to energy minimization using the MM2 method and then saved as PDB 
extension files, which can be accessed using the AutoDock Vina (ADT) interface. ADT 1.5.6 software version was used for molecular docking study.
Results: Various molecular targets were selected (D2/D3, D2, A2A, and MAO-B) and studied for Pardoprunox, Istradefylline, Rasagiline, and 
Bromocriptine. Pardoprunox, Istradefylline, and Bromocriptine had more affinity with their corresponding receptor with −6.9, −8.5, and −9.4 kcal/mol 
binding affinity, respectively, except Rasagiline, who has less affinity with its corresponding receptor (−6.4kcal/mol) and shown better affinity with 
3pbl receptor (−6.7 kcal/mol).
Conclusion: Pardoprunox, Istradefylline, and Bromocriptine were found to act on D2/D3 (3pbl), A2A (3pwh), and D2 (4yyw), respectively, whereas 
Rasagiline found to be act on D2/D3 (3pbl) receptor. The results help in prediction of mechanism and interaction to various Parkinson’s disease 
targets.
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INTRODUCTION
Neurological disorders cause significant morbidity, mortality, disability, 
and socioeconomic losses and reduce the quality of life [1]. Few Indian 
neuroepidemiological studies have estimated the load of neurological 
diseases [2,3]. Nearly 33 million Indians have neurological disorders 
and they occur twice as often in rural areas [4]. Parkinson’s disease 
(PD) is one of the neurological diseases that affect the ability to perform 
common daily activities. Most of the people with the PD will experience 
affect motor and non-motor movement. The most common motor 
symptoms of PD are tremor (a form of rhythmic shaking), rigidity of 
the muscles, and slowness of movement (called bradykinesia). A person 
with PD may also have trouble with posture, fatigue, anxiety, bad facial 
expression, loss of smell, poor balance, depression, failure in walking, 
sleep problems, and constipation, which are common non-motor 
symptoms of PD among others [5,6].
The cause of PD is still unknown; till, however, there is some evidence 
that genetics and environmental factors or a combination of both 
have a big role in PD [7]. It is also possible that there may be more 
than one cause of PD. PD is a multifaceted disease involving the 
activation of several cellular pathways in dopaminergic neurons. 
These pathways include MPTP toxicity, alterations in neurotransmitter 
levels, oxidative stress, glutamate toxicity, mitochondrial dysfunction, 
neuroinflammation, alterations in gene regulation, protein aggregation, 
and heavy metal poisoning [8]. These mechanisms share overlapping 
and redundant features and cause injury to the neurons. Diagnosis of 
PD in population-based studies is another important issue, and the 
presence of at least two of the three cardinal features of PD resting 
tremor, bradykinesia, rigidity without other causes of Parkinsonism is 
acceptable [9]. There is no curative therapy for PD till date. The two 
main approaches to treatment practiced are symptomatic therapy and 
protective therapy. Dopamine analogs and anticholinergic agents help 
to restore the dopamine levels this results in improving the movement 
disabilities, thus these drugs come under symptomatic therapy. 
Anticholinergic agents carry with them serious central nervous system 
adverse effects such as cognitive impairment and hallucination; other 
side effects are constipation and dryness of mouth. Protective therapy 
helps to reduce the side effects of drugs by their free radical scavenging 
properties, selegiline, and Vitamin E comes under this category [10]. The 
introduction of levodopa proved a landmark discovery in the treatment 
of PD, but the peripheral decarboxylation is a major limitation of the 
drug. Adjuvant therapy carbidopa is given to increase the bioavailability 
of levodopa in the brain. The present therapies although good for the 
management of the disease but as long-term use side effects occur. 
There is the tremendous research going on the new drugs approaches 
for the treatment of PD, which is believed to carry the minimum 
side effects. As per the several studies, it is concluded that one of the 
reasons of PD pathogenesis is oxidative damage. A lot of antioxidant 
drugs such as selegiline, bromocriptine, ropinirole, pramipexole, and 
many more are used to treat the oxidative stress, as with great benefits 
they have a long list of side effects that cannot be controlled during the 
therapy, so the new drugs under the studies will be taken and will show 
more effect in the treatment of the disease (Fig. 1) [10]. Recent years, 
atypical antipsychotics, such as phenothiazines and butyrophenones, 
which block postsynaptic receptors for dopamine receptor and 
cause extrapyramidal symptoms generally, resemble Parkinsonism. 
Antiemetics such as prochlorperazine and metoclopramide may 
also cause Parkinsonism. Reserpine produces a Parkinsonism-
like symptoms by depleting dopamine available for release by the 
presynaptic neurons [11,12].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11s2.28512
Research Article
Recent Trends in Biomedical Sciences-2018 (RTBS-2018)
29
Asian J Pharm Clin Res, Vol 11, Special issue 2, 2018, 28-32
 Dorice et al.
In addition to the therapeutic challenges, other antipsychotics like 
clonidine were found to be safe in the treatment of PD psychosis 
without degenerating Parkinsonism or causing other adverse effects, 
there are challenges related conducting the trials and many issues 
pertaining to optimal trial design, inclusion/exclusion criteria, 
subject recruitment, and study completion PD psychosis. Apart from 
these atypical antipsychotic drugs, other drugs which are not yet 
in the market, but under phase III such as SLV308 (Pardoprunox) 
and KW6002 (Istradefylline) was also found to be effective to treat 
PD [13]. The current research work was aimed to evaluate the 
mechanism of anti-Parkinson’s drugs, which are approved or under 
clinical trials.
METHODS
To evaluate the mechanistic aspect of anti-Parkinson drugs under clinical 
trial, it is necessary to have the knowledge of the binding interaction of 
existing drugs with their respective target receptors. By taking into the 
considerations of various aspects of ligand-receptor interaction, a new 
scaffold can be developed. This can be achieved by computer-aided drug 
design, especially molecular docking [14-17]. Hence, we used Autodock 
Vina (ADT) 1.5.6 software [18] to find out the binding affinity (Kcal/mol) 
and compared with various targets. The selected anti-Parkinson agent’s 
structure was drawn by ChemBioDraw ultra and thereafter converted to 
the 3D structure using ChemBioDraw 3D. All structures were optimized 
Fig. 1: Common anti-Parkinson’s agents
Fig. 2: Selected anti-Parkinsonism agents for comparative study of mechanism
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Table 1: Comparison of estimated free energy of binding of the investigated ligands with different receptors
S. No. Receptors Drugs Binding affinity (Kcal/mol) Target receptors
3pbl 3pwh 2vz2 4yyw
D2/D3 agonist −6.9 NA NA −6.3
A2A antagonist
 
−8.5 −8.5 NA −7.4
MAO-B selective inhibitor
 
−6.7 −2.9 −6.4 −4.8
Pure D2 −8.3 −3.9 NA −3.9
*NA: No binding
by energy minimization using MM2 method [19] before ligand 
preparation and saved to pdb format. For comparative mechanistic 
study, proteins (receptor) such as D2/D3 (3pbl), A2A (3pwh), MAO-B 
(2vz2), and D2 (4yyw) were selected and downloaded from Protein Data 
Bank [20]. The results were analyzed for various interactions between 
ligand and target receptor by ADT.
RESULTS AND DISCUSSION
The main purpose of this study is to find out the mechanism of anti-
Parkinson agents by investigated them to target proteins (receptors). 
Various molecular targets were selected, i.e. D2/D3, D2, A2A, and 
MAO-B and studied for Pardoprunox, Istradefylline, Rasagiline, and 
Bromocriptine as shown in Fig. 2.
All structures were drawn through ChemBioDraw 2D software to study 
the stereochemical effect and then converted to 3D structures using 
ChemBioDraw 3D software a later saved as pdb files so that it can be 
accessed by the ADT software. Different proteins were downloaded 
from the Protein Data Bank site rcsb.org specifically protein with code 
D2/D3 (3pbl), A2A (3pwh), MAO-B (2vz2), and D2 (4yyw) for this study.
All the chosen molecules were analyzed utilizing the ADT molecular 
modeling software. At first, the protein was validated by docking with 
the extracted ligand (Fig. 3). Ligands were prepared by the including of 
polar hydrogens, recognizing root, and changing over it to pdbqt, while 
proteins were set up by evacuating water molecules, repairing missing 
atoms, including polar hydrogens, as well as the Kollman charges. 
Further, the grid box was created keeping the ligand as middle; from that 
configuration file, “conf.txt” was prepared. At last, through command 
prompt docking was performed utilizing for ADT as “program files\the 
scripps research institute\vina\vina.exe --config conf.txt --log log.txt.” 
It produced the record the docking score or output file with binding 
affinity (Kcal/mol), comparative results were examined and presented 
in Table 1.
Binding interaction of Pardoprunox, Istradefylline, Rasagiline, and 
Bromocriptine was analyzed in detail. Pardoprunox, Istradefylline, and 
Bromocriptine had more affinity with their corresponding receptor 
binding and had scored −6.9, −8.5, and −9.4 Kcal/mol, respectively, 
except Rasagiline who has less affinity with its corresponding receptor 
(−6.4 Kcal/mol) but showed a better affinity with 3pbl receptor 
(−6.7 Kcal/mol). Therefore, cross-docking each ligand with different 
other receptors was analyzed and discussed below.
Pardoprunox has no affinity on 2vz2 and 3pwh receptor but has less 
affinity on 4yyw with a score of −6.3 Kcal/mol. Istradefylline has no 
affinity on 2vz2, less affinity with 4yyw (−7.4 Kcal/mol) compared to 
the affinity that it has with 3pbl (−8.5 Kcal/mol) which is same to that 
Fig. 3: Extracted and preparation of ligand from protein
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with 3pwh. Rasagiline showed affinity with almost all the receptors with 
−6.7, −4.8, and −2,9 Kcal/mol binding affinities with 3pbl, 4yyw, and 
3pwh, respectively. We found that Rasagiline has more binding affinity 
with 3pbl and therefore it can be a partial D2/D3 receptor agonist. 
Bromocriptine has no affinity with 2vz2 receptor, less affinity with 3pwh 
(−3.9 Kcal/mol), and better with 3pbl (−8.3 Kcal/mol) (Table 1).
To understand the binding interaction, and in-depth analysis was done 
for SLV308 (Pardoprunox) (Figs. 4 and 5). We found that Pardoprunox 
binds on the receptor 3pbl through interacting with various amino 
acid residues, i.e. ILE183, VAL107, PHE106, TYR365, PHE345, and 
HIS349. The NH group of Pardoprunox binds very closely to NH group 
of backbone of isoleucine 183 (ILE183) to form hydrogen binding; 
similarly, its carbonyl group has a hydrogen bonding to NH of histidine 
349 (HIS349) present on its receptor. Although compared to other drugs 
interaction, it has more binding affinity with its receptor than Rasagiline 
ligand with 2vz2 receptor and Istradefylline ligand with 3pwh receptor, 
less than that of bromocriptine ligand with 4yyw receptor. By these 
interactions, we can understand that more is the interaction of the 
ligand with the receptor suggests the mechanism of drug.
CONCLUSION
We studied binding affinities of different novel anti-Parkinsonism 
drugs under clinical trials and compared with currently used drug 
Bromocriptine using ADT molecular software. However, the study 
has been done by docking each drug with its original receptor and by 
cross-docking them with different other receptors to determine on 
what receptor each drug has better affinity. Bromocriptine showed 
the maximum activity on 4yyw receptor (D2 receptor) with a binding 
affinity of −9.4 Kcal/mol. Rasagiline showed better affinity with receptor 
3pbl (D2/D3 receptor) with a binding affinity of −6.7 kcal/mol and 
moderate affinity with receptor (2vz2 (MAO-B receptor). Istradefylline 
showed more binding affinity of −8.5 Kcal/mol to receptor 3phw (A2A 
receptor) and equally on 3pbl (D2/D3 receptor), whereas Pardoprunox 
showed −6.9 Kcal/mol binding affinity on receptor 3pbl (D2/D3 
receptor). Therefore, we can suggest the mechanistic role of these drugs 
on the base of better binding affinities Bromocriptine, Istradefylline 
(KW6002), Rasagiline, and Pardoprunox (SLV308) as D2 and partial 
D2/D3 agonist.
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